Kidney Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 122 pages | ID: K3E18FD2F61AEN
Global Markets Direct

Abstracts

Kidney Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Drugs In Development, 2022, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 37 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Kidney Fibrosis - Overview
Kidney Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Kidney Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Kidney Fibrosis - Companies Involved in Therapeutics Development
Kidney Fibrosis - Drug Profiles
Kidney Fibrosis - Dormant Projects
Kidney Fibrosis - Discontinued Products
Kidney Fibrosis - Product Development Milestones
Featured News & Press Releases
Jul 04, 2022: AD-214 program modified to maximise partnering options, extends cash runway
Jan 04, 2022: Alentis Therapeutics starts first-in-human clinical trial for the treatment of liver and kidney fibrosis
Sep 27, 2021: AdAlta announces new preclinical data presented at “Discovery on Target” meeting
Sep 08, 2021: RedHill’s opaganib reduces kidney fibrosis in preclinical study
Jun 22, 2020: Hepion Pharmaceuticals' CRV431 demonstrates efficacy in kidney fibrosis
Nov 11, 2019: Liminal Biosciences presents new preclinical data on PBI-4610 at ASN Kidney Week 2019
Oct 24, 2019: Liminal BioSciences announces upcoming presentation on drug candidate PBI-4610 at ASN kidney week 2019
Jul 18, 2019: Genkyotex to launch Phase II pulmonary fibrosis trial in US
Jan 14, 2019: Nash Pharmaceuticals provides update on Kidney Disease drug candidate NP-160
Jan 14, 2019: Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease
Nov 29, 2018: Kadmon presents data on New ROCK Inhibitor clinical candidate at Anti-Fibrotic Drug Development Summit
Nov 19, 2018: Nash Pharmaceuticals announces positive pre-clinical results for its lead compound NP-135 in chronic kidney disease
Aug 30, 2018: VBL Therapeutics announces publication of positive new data on its Lecinoxoid drug candidates for the treatment of renal fibrosis
Nov 13, 2017: AdAlta to present at Anti-Fibrotic Drug Development Summit in Boston
Sep 06, 2017: Pharmaxis Announces Anti Fibrotic LOXL2 Program Clears Preclinical Development And Set To Commence Phase 1 Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Kidney Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Kidney Fibrosis - Pipeline by Accendatech Co Ltd, 2022
Kidney Fibrosis - Pipeline by AdAlta Ltd, 2022
Kidney Fibrosis - Pipeline by Alentis Therapeutics AG, 2022
Kidney Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, 2022
Kidney Fibrosis - Pipeline by Anagenics Ltd, 2022
Kidney Fibrosis - Pipeline by Angion Biomedica Corp, 2022
Kidney Fibrosis - Pipeline by AstraZeneca Plc, 2022
Kidney Fibrosis - Pipeline by BiOrion Technologies BV, 2022
Kidney Fibrosis - Pipeline by CohBar Inc, 2022
Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, 2022
Kidney Fibrosis - Pipeline by Evotec SE, 2022
Kidney Fibrosis - Pipeline by Future Medicine Co Ltd, 2022
Kidney Fibrosis - Pipeline by Galapagos NV, 2022
Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, 2022
Kidney Fibrosis - Pipeline by GenKyoTex SA, 2022
Kidney Fibrosis - Pipeline by Hepion Pharmaceuticals Inc, 2022
Kidney Fibrosis - Pipeline by iBio Inc, 2022
Kidney Fibrosis - Pipeline by InSilico Medicine, 2022
Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, 2022
Kidney Fibrosis - Pipeline by Jiangxi Jemincare Group Co Ltd, 2022
Kidney Fibrosis - Pipeline by Kadmon Holdings Inc, 2022
Kidney Fibrosis - Pipeline by Liminal BioSciences Inc, 2022
Kidney Fibrosis - Pipeline by Max Biopharma Inc, 2022
Kidney Fibrosis - Pipeline by Mission Therapeutics Ltd, 2022
Kidney Fibrosis - Pipeline by NB Health Laboratory Co Ltd, 2022
Kidney Fibrosis - Pipeline by Novo Nordisk AS, 2022
Kidney Fibrosis - Pipeline by Osteoneurogen Inc, 2022
Kidney Fibrosis - Pipeline by Pharmaxis Ltd, 2022
Kidney Fibrosis - Pipeline by RedHill Biopharma Ltd, 2022
Kidney Fibrosis - Pipeline by Rubedo Life Sciences Inc, 2022
Kidney Fibrosis - Pipeline by Sanofi, 2022
Kidney Fibrosis - Pipeline by Scholar Rock Inc, 2022
Kidney Fibrosis - Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2022
Kidney Fibrosis - Pipeline by Senolytic Therapeutics Inc, 2022
Kidney Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, 2022
Kidney Fibrosis - Pipeline by Transcenta Holding Ltd, 2022
Kidney Fibrosis - Pipeline by UCB SA, 2022
Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, 2022
Kidney Fibrosis - Pipeline by Vectus Biosystems Ltd, 2022
Kidney Fibrosis - Dormant Projects, 2022
Kidney Fibrosis - Dormant Projects, 2022 (Contd..1)
Kidney Fibrosis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Kidney Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022